Hospital acquired infections
Patients admitted to or visiting hospitals can develop multiple infections, which are known as hospital-acquired infections (HAIs), or, simply, hospital infections. These conditions generally spread within nursing homes, dialysis centres, rehabilitation centres, outpatient surgery centres, and hospitals. Various bacterial, fungal, and viral pathogens can cause hospital infections. Intensive care units are also a common source of HAIs, which can be treated using antimicrobial drugs. Some therapeutic drugs available for these diseases are CAZ AVI, Surotomycin, MK-3415A, and Ceftolozane.
The growing susceptibility of the neonatal population to HAIs and the booming supply of drugs for these conditions is likely to lead to massive growth in the hospital infection therapeutics market in the coming years. Moreover, the lack of skilled nursing staff in healthcare settings, especially in emerging economies, is a key factor making therapeutic drugs more important. In many countries, these factors will offer pharmaceutical companies the opportunity to increase their production capacity in the coming years.
The number of hospitals is also rising worldwide, primarily due to government efforts to make healthcare more accessible. The World Bank reports the number of hospital beds per 1,000 people around the world increased to 2.894 in 2017 from 2.462 in 2005. A higher number of hospital beds means a larger number of hospital patients, which translates into a higher incidence of various HAIs. Ultimately, this will increase the demand for therapeutic drugs in the coming years.
North America has emerged as the hospital infection therapeutics market leader. The reason is the higher ratio of hospitals to the population of the region compared to other parts of the world. The surging population of ageing people in the continent and the increasing number of multi-drug-resistant microbial pathogens are also significant reasons leading to the rising demand for therapeutic drugs. APAC is also witnessing a rising demand for therapeutic drugs, especially in China and India, due to the growing prevalence of HAIs.
[edit] Related articles on Designing Buildings
Featured articles and news
The act of preservation may sometimes be futile.
Twas the site before Christmas...
A rhyme for the industry and a thankyou to our supporters.
Plumbing and heating systems in schools
New apprentice pay rates coming into effect in the new year
Addressing the impact of recent national minimum wage changes.
EBSSA support for the new industry competence structure
The Engineering and Building Services Skills Authority, in working group 2.
Notes from BSRIA Sustainable Futures briefing
From carbon down to the all important customer: Redefining Retrofit for Net Zero Living.
Principal Designer: A New Opportunity for Architects
ACA launches a Principal Designer Register for architects.
A new government plan for housing and nature recovery
Exploring a new housing and infrastructure nature recovery framework.
Leveraging technology to enhance prospects for students
A case study on the significance of the Autodesk Revit certification.
Fundamental Review of Building Regulations Guidance
Announced during commons debate on the Grenfell Inquiry Phase 2 report.
CIAT responds to the updated National Planning Policy Framework
With key changes in the revised NPPF outlined.
Councils and communities highlighted for delivery of common-sense housing in planning overhaul
As government follows up with mandatory housing targets.
Comments
[edit] To make a comment about this article, or to suggest changes, click 'Add a comment' above. Separate your comments from any existing comments by inserting a horizontal line.